S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
"The Bull Market Is Officially OVER"  (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
"The Bull Market Is Officially OVER"  (Ad)pixel
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
"The Bull Market Is Officially OVER"  (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
"The Bull Market Is Officially OVER"  (Ad)pixel
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
"The Bull Market Is Officially OVER"  (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
"The Bull Market Is Officially OVER"  (Ad)pixel
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
"The Bull Market Is Officially OVER"  (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
"The Bull Market Is Officially OVER"  (Ad)pixel
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
NASDAQ:GILD

Gilead Sciences - GILD Stock Forecast, Price & News

$89.03
+1.13 (+1.29%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$86.55
$89.07
50-Day Range
$61.69
$89.03
52-Week Range
$57.17
$89.07
Volume
6.73 million shs
Average Volume
7.67 million shs
Market Capitalization
$111.66 billion
P/E Ratio
33.60
Dividend Yield
3.32%
Price Target
$83.45

Gilead Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
5.5% Downside
$84.10 Price Target
Short Interest
Healthy
1.65% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.70mentions of Gilead Sciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$1.82 M Sold Last Quarter
Proj. Earnings Growth
-4.23%
From $7.09 to $6.79 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

94th out of 1,052 stocks

Biological Products, Except Diagnostic Industry

14th out of 173 stocks

GILD stock logo

About Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Stock News Headlines

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (GILD)
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
2 Reasons This Stock Could Outperform in 2023
The 3 Best Dividend Stocks to Purchase Right Now
What Does Gilead Sciences' Debt Look Like?
GILD vs. HALO: Which Stock Is the Better Value Option?
Buy this Medical Sector Pioneer Stock
Gilead Sciences' Debt Overview
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Company Calendar

Ex-Dividend for 9/29 Dividend
9/14/2022
Dividend Payable
9/29/2022
Last Earnings
10/27/2022
Today
12/03/2022
Ex-Dividend for 12/29 Dividend
12/14/2022
Dividend Payable
12/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/07/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GILD
CUSIP
37555810
Employees
14,400
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$84.10
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$69.00
Forecasted Upside/Downside
-6.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
18 Analysts

Profitability

Net Income
$6.23 billion
Pretax Margin
16.74%

Debt

Sales & Book Value

Annual Sales
$27.31 billion
Cash Flow
$9.08 per share
Book Value
$16.79 per share

Miscellaneous

Outstanding Shares
1,254,240,000
Free Float
1,252,237,000
Market Cap
$111.66 billion
Optionable
Optionable
Beta
0.45

Social Links


Key Executives

  • Mr. Daniel P. O'Day (Age 58)
    Chairman & CEO
    Comp: $6.09M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 52)
    Exec. VP & CFO
    Comp: $2.55M
  • Ms. Johanna MercierMs. Johanna Mercier (Age 52)
    Chief Commercial Officer
    Comp: $2.92M
  • Dr. Merdad V. Parsey M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $2.68M
  • Ms. Diane E. WilfongMs. Diane E. Wilfong (Age 60)
    Sr. VP, Corp. Controller & Chief Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    VP of Investor Relations
  • Ms. Deborah H. Telman (Age 57)
    Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Jyoti K. Mehra (Age 46)
    Exec. VP of HR
  • Dr. Michael Quigley Ph.D.
    Sr. VP of Research Biology
  • Dr. Linda Slanec Higgins Ph.D. (Age 60)
    Sr. VP & Head of External Innovation













GILD Stock - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GILD shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price forecast for 2023?

18 equities research analysts have issued 1 year price targets for Gilead Sciences' stock. Their GILD share price forecasts range from $69.00 to $105.00. On average, they predict the company's share price to reach $84.10 in the next twelve months. This suggests that the stock has a possible downside of 5.5%.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2022?

Gilead Sciences' stock was trading at $72.61 at the start of the year. Since then, GILD shares have increased by 22.6% and is now trading at $89.03.
View the best growth stocks for 2022 here
.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 20,730,000 shares, an increase of 8.7% from the October 31st total of 19,070,000 shares. Based on an average daily trading volume, of 8,130,000 shares, the days-to-cover ratio is currently 2.5 days.
View Gilead Sciences' Short Interest
.

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our GILD earnings forecast
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, October, 27th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.46. The biopharmaceutical company earned $7.04 billion during the quarter, compared to the consensus estimate of $6.12 billion. Gilead Sciences had a trailing twelve-month return on equity of 38.51% and a net margin of 12.29%.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, October 27th. Stockholders of record on Thursday, December 15th will be paid a dividend of $0.73 per share on Thursday, December 29th. This represents a $2.92 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date is Wednesday, December 14th.
Read our dividend analysis for GILD
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 3.32%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 110.19%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 43.00% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of $6.95-$7.15 for the period, compared to the consensus estimate of $6.54. The company issued revenue guidance of $25.90 billion-$26.20 billion, compared to the consensus revenue estimate of $25.25 billion.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.24%), Vanguard Group Inc. (8.94%), State Street Corp (4.72%), Bank of New York Mellon Corp (1.23%), Renaissance Technologies LLC (0.80%) and UBS Asset Management Americas Inc. (0.79%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends
.

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $89.03.

How much money does Gilead Sciences make?

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $111.67 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $2.65 on an earnings per share basis.

How many employees does Gilead Sciences have?

The company employs 14,400 workers across the globe.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.

This page (NASDAQ:GILD) was last updated on 12/3/2022 by MarketBeat.com Staff